How I Treat AML: Which Patients Might Benefit from Hypomethylating Agents in the Frontline and at Relapse?
Though hypomethylating agents (HMAs) have been available for about half a century, their use in acute myeloid leukemia (AML) has increased dramatically over the last decade. Clinicians are faced with difficult choices as to when these drugs should be used in patients with AML, in whom, for what period of time, and combined with what other agents. The objective of this presentation is to tackle these questions using challenging cases that highlight the latest clinical, molecular, and translational data.
Gail J. Roboz
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members